VEGFR2/CD309 抗体 (AA 20-678)
Our Local Distributor
北京 101111
Quick Overview for VEGFR2/CD309 抗体 (AA 20-678) (ABIN616030)
抗原
See all VEGFR2/CD309 (VEGFR2) 抗体适用
宿主
克隆类型
标记
应用范围
-
-
抗原表位
- AA 20-678
-
特异性
- This antibody detects CD309 / VEGFR-2 / Flk-1.
-
交叉反应 (详细)
- Species reactivity (tested):Human
-
纯化方法
- Protein-A purified
-
免疫原
- Highly pure (>95%) recombinant human esKDR (Ala20-Pro678) derived from insect cells
-
亚型
- IgG
-
-
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
限制
- 仅限研究用
-
-
-
溶解方式
- Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/mL.
-
缓冲液
- PBS, pH 7.2
-
注意事项
- Avoid repeated freezing and thawing.
-
储存条件
- 4 °C/-20 °C
-
储存方法
- The lyophilized antibody is stable at room temperature for up to 1 month. Following reconstitution antibody can be stored at 2-8 °C for up to two weeks or (in aliquots) at -20 °C for longer.
-
-
- VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))
-
别名
- CD309 / VEGFR-2 / Flk-1
-
背景
- Disruption of the precise balance of positive and negative molecular regulators of blood and lymphatic vessel growth can lead to myriad diseases. Although dozens of natural inhibitors of hemangiogenesis have been identified, an endogenous selective inhibitor of lymphatic vessel growth has not to our knowledge been previously described. A splice variant of the gene encoding vascular endothelial growth factor receptor-2 (VEGFR-2) that encodes a secreted form of the protein, designated endogenous soluble VEGFR-2 (esVEGFR-2/KDR) has been described. The endogenous soluble esKDR inhibits developmental and reparative lymphangiogenesis by blocking VEGF-C function. Tissue-specific loss of esKDR in mice induced, at birth, spontaneous lymphatic invasion of the normally alymphatic cornea and hyperplasia of skin lymphatics without affecting blood vasculature. Administration of esKDR inhibited lymphangiogenesis but not hemangiogenesis induced by corneal suture injury or transplantation, enhanced corneal allograft survival and suppressed lymphangioma cellular proliferation. Naturally occurring esKDR thus acts as a molecular uncoupler of blood and lymphatic vessels, modulation of esKDR might have therapeutic effects in treating lymphatic vascular malformations, transplantation rejection and, potentially, tumor lymphangiogenesis and lymphedema. Recombinant human esKDR generated by alternative splicing consist of the first 6 Ig-like loops followed by the unique C-terminal end: CGRETILDHSAEAVGMP.Synonyms: FLK1, KDR, Kinase NYK, Kinase insert domain receptor, Protein-tyrosine kinase receptor Flk-1, VEGF Receptor 2, VEGFR2, Vascular endothelial growth factor receptor 2
-
基因ID
- 3791
-
NCBI登录号
- NP_002244
-
UniProt
- P35968
-
途径
- RTK signaling, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling
抗原
-